对加拿大药品统一审评的分析及其对我国的启示  

Analysis of the Canadian Common Drug Review and Its Implication for Chinese Drug Review

作　　者：常精华[1] 孙利华[1] 郭朗[1] 

机构地区：[1]沈阳药科大学工商管理学院,沈阳市110016

出　　处：《中国药房》2008年第25期1921-1923,共3页China Pharmacy

摘　　要：目的:为优化我国"医保"药品遴选和新药审评提供参考。方法:介绍加拿大药品统一审评人员的职责及审评流程,分析其药品审评中存在的问题及其采取的对策。结果与结论:加拿大为解决药品统一审评中存在的过多的延迟和繁琐、缺乏透明度和责任制等问题,采取了相应的措施,如限定审评时间、开设远程电子会议、建立公众委员会等。我国可借鉴加拿大的相关经验,寻求保证我国"医保"药品遴选和新药审评的经济性、及时性和透明性的途径。OBJECTIVE： To provide references for optimizing the selection of medical insurance drugs and drug review in China. METHODS： The Canadian common drug reviewers＇ basic duties and the Canadian common drug review process were introduced, and the existing problems in drug review and the countermeasures were analyzed. RESULTS ＆ CONCLUSIONS： In view of the problems occurred in Canadian drug review such as redundant delay and tedious, lack of transparence and job responsibility system and so on, the corresponding measures had been taken such as defining drug review time, helding long range e - meeting, and establishing public committee etc. Chinese common drug review should draw experiences from the Canadian drug review to explore a more economical, timely and transparent practice in Chinese medical insurance drug selection and drug review.

关 键 词：加拿大 药品统一审评 中国 启示 

分 类 号：R95[医药卫生—药学] F840.684[经济管理—保险]